BRCA1突变携带者卵巢切除后激素替代治疗与乳腺癌风险
这项前瞻性纵向队列研究纳入872例无癌症史的BRCA1突变携带者,平均随访7.6年,评估卵巢切除后激素替代治疗(HRT)与乳腺癌风险的关联。
要点
- 卵巢切除后使用任何类型HRT未增加BRCA1突变携带者乳腺癌风险。
- 单用雌激素者10年累积乳腺癌发病率为12%,低于联合孕激素者的22%。
- 含孕激素HRT的潜在不良影响需进一步研究。
核心结论
- 卵巢切除后使用雌激素不增加BRCA1突变携带者乳腺癌风险,应告知考虑预防性手术的携带者HRT是安全的。
- 含孕激素HRT的可能不良影响需进一步研究。
研究设计与样本
- 前瞻性纵向队列研究,1995-2017年从17个国家80个中心纳入BRCA1/BRCA2突变携带者,平均随访7.6年。
- 分析纳入872例无个人癌症史、入组后行双侧卵巢切除术的BRCA1突变携带者,平均年龄43.4(8.5)岁。
- 每2年发放随访问卷获取HRT使用详细信息,采用左截断Cox比例风险分析估计风险比(HR)和95%CI。
主要发现
- 共诊断92例(10.6%)新发乳腺癌。
临床怎么用
- 对考虑预防性双侧输卵管卵巢切除术的BRCA1突变携带者,可告知术后使用雌激素HRT不增加乳腺癌风险。
- 处方含孕激素HRT时应权衡其可能的不良影响,并进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy is associated with an increased risk of breast cancer has not been evaluated in a prospective study. OBJECTIVE: To determine the association between HRT use and BRCA1-associated breast cancer. DESIGN, SETTING, AND PARTICIPANTS: A prospective, longitudinal cohort study of BRCA1 and BRCA2 mutation carriers from 80 participating centers in 17 countries was conducted between 1995 and 2017 with a mean follow-up of 7.6 years. Participants had sought genetic testing for a BRCA1 or BRCA2 mutation because of a personal or family history of breast and/or ovarian cancer. Carriers of BRCA1 mutation with no personal medical history of cancer who underwent bilateral oophorectomy following enrollment were eligible for the cohort study. EXPOSURES: A follow-up questionnaire was administered every 2 years to obtain detailed information on HRT use. A left-truncated Cox proportional hazard analysis was used to estimate the hazard ratios (HRs) and 95% CIs associated with the initiation of HRT use postoophorectomy. MAIN OUTCOMES AND MEASURES: Incident breast cancer. RESULTS: A total of 872 BRCA1 mutation carriers with a mean postoophorectomy follow-up period of 7.6 years (range, 0.4-22.1) were included in this study. Mean (SD) age of participants was 43.4 (8.5) years. Among these, 92 (10.6%) incident breast cancers were diagnosed. Overall, HRT use after oophorectomy was not associated with an increased risk of breast cancer. The HR was 0.97 (95% CI, 0.62-1.52; P = .89) for ever use of any type of HRT vs no use; however, the effects of estrogen alone and combination hormonal therapy were different. After 10 years of follow-up, the cumulative incidence of breast cancer among women who used estrogen-alone HRT was 12% compared with 22% among women who used estrogen plus progesterone HRT (absolute difference, 10%; log rank P = .04). CONCLUSIONS AND RELEVANCE: These findings suggest that use of estrogen after oophorectomy does not increase the risk of breast cancer among women with a BRCA1 mutation and should reassure BRCA1 mutation carriers considering preventive surgery that HRT is safe. The possible adverse effect of progesterone-containing HRT warrants further study.
引用
- Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol. 2018. PMID: 29710224. doi:10.1001/jamaoncol.2018.0211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。